| P/E (FY) | — | Sales (TTM) | $708.2M |
| Earnings (TTM) | -$188.3M | ROE | −252.11% |
| Net Margin | −28.69% | ROIC | — |
| Debt / Equity | 2.13 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Axsome Therapeutics, Inc. is a biopharmaceutical company developing therapies for central nervous system disorders in the United States. Its commercial portfolio includes Auvelity (dextromethorphan-bupropion) for major depressive disorder in adults, Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea, and Symbravo (meloxicam-rizatriptan), also known as AXS-07, for the acute treatment of migraine.
| Market Cap | $12.05B | Trading Days | 2683 |
| 52W High | 260.19 |
| 52W Low | 96.09 |
| % Off High | −9.99% |
| YTD | 28.23% | 1Y | 133.29% |
| 3Y | 197.66% | 5Y | 343.48% |
| 10Y | 2842.21% | Since incept. (ann.) | 36.02% |
Product 99% · Royalty And Milestone Revenue 1%
| Ann. Volatility (1Y) | 42.74% | Ann. Volatility (3Y) | 44.27% |
| Sharpe (1Y) | 2.21 | Sharpe (3Y) | 1.06 |
| Max Drawdown (1Y) | −18.50% | Max Drawdown (3Y) | −32.69% |
| Beta (3Y, vs SPY) | 1.20 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $12.05B | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.65B | 33.5 |
| ELAN | Elanco Animal Health Inc | $12.69B | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $12.71B | — |
| GPCR | Structure Therapeutics Inc. | $10.47B | — |
| SMMT | Summit Therapeutics Inc. | $10.45B | — |
| QNRX | Quoin Pharmaceuticals, Ltd. | $14.39B | — |
| CYTK | CYTOKINETICS INC | $10.03B | — |
| CORT | CORCEPT THERAPEUTICS INC | $9.78B | 111.1 |
| IONS | IONIS PHARMACEUTICALS INC | $9.25B | — |
| JAZZ | Jazz Pharmaceuticals plc |
| $16.03B |
| — |
| NUVL | Nuvalent, Inc. | $9.01B | — |
